John T. Treace Sells $3.56M of Treace Medical Concepts Inc (TMCI) — SEC Form 4, Oct 22, 2021
Open-Market Net Sale · SEC Form 4
−$3,555,011
10b5-1 Plan (Partial)
Equity position changed by +2.3%
Equity Position
11.1M sh
10,832,893 → 11,076,709
Equity Change
+2.3%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| John T. Treace CIK 0001856380 |
Director
CEO
10% Owner
|
John T. Treace at Treace Medical Concepts Inc
Full insider history
Bought (12 mo)
$1,351,631
Sold (12 mo)
—
More from this insider at Treace Medical Concepts Inc
| 2026-08-24 | Buy | +$246,654 | View |
| 2026-06-11 | Buy | +$210,968 | View |
| 2026-06-01 | Buy | +$177,915 | View |
| 2026-05-28 | Buy | +$340,589 | View |
| 2026-05-14 | Buy | +$375,505 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2 | 2021-10-20 | S - Sale 10b5-1 | 22,612 D | $24.79 | -$560,531 | 5,894,968 | Direct |
| Common StockF1F3 | 2021-10-20 | S - Sale 10b5-1 | 8,215 D | $25.37 | -$208,377 | 5,886,753 | Direct |
| Common StockF1F4 | 2021-10-21 | S - Sale 10b5-1 | 34,325 D | $19.89 | -$682,862 | 5,852,428 | Direct |
| Common StockF1F5 | 2021-10-21 | S - Sale 10b5-1 | 26,701 D | $20.67 | -$551,998 | 5,825,727 | Direct |
| Common StockF1F6 | 2021-10-21 | S - Sale 10b5-1 | 2,768 D | $21.49 | -$59,498 | 5,822,959 | Direct |
| Common StockF1F7 | 2021-10-21 | S - Sale 10b5-1 | 8,207 D | $23.07 | -$189,340 | 5,814,752 | Direct |
| Common StockF1F8 | 2021-10-21 | S - Sale 10b5-1 | 4,044 D | $23.86 | -$96,470 | 5,810,708 | Direct |
| Common StockF1 | 2021-10-21 | S - Sale 10b5-1 | 39 D | $24.50 | -$956 | 5,810,669 | Direct |
| Common StockF1F9 | 2021-10-22 | S - Sale 10b5-1 | 57,534 D | $20.74 | -$1,193,238 | 5,753,135 | Direct |
| Common StockF1F10 | 2021-10-22 | S - Sale 10b5-1 | 555 D | $21.16 | -$11,743 | 5,752,580 | Direct |
| Common StockF12 | 2021-09-07 | A - Award/Grant | 408,816 A | $0.00 | — | 408,816 | Indirect |
Footnotes (12)
- F1
- Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Show more
- F2
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.21 to $25.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F3
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.22 to $25.69 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F4
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.21 to $20.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F5
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.22 to $21.16 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F6
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.98 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F7
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.36 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F8
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.38 to $24.25 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F9
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.12 to $21.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F10
- The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $21.14 to $21.21 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Show more
- F11
- The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. Show more
- F12
- The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as Trustee or Co-Trustee. Show more
Related filings at Treace Medical Concepts Inc
Institutional Holders
13F holders · Jun 30, 2026
115
institutional managers reporting a position
Largest by reported value
- Armistice Capital, Llc $25.3M
- Bank Of America Corporation $13.2M
- Gagnon Securities Llc $12.1M
5%+ Holders · 13D/G
4 filers
-
John T. Treace 19.2%
Other insiders at Treace Medical Concepts Inc
GET /v1/forms/4/0001567619-21-018627
API docs
View Original SEC Filing